doi:10.1371/journal.pone.0033944 Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ et al (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
Among these, glucagon-like peptide-1 (GLP-1) receptor agonists, which are already approved for weight management and type 2 diabetes, have shown promise
You might not get a full response at three months
Advanced: Consume 1 serving (30 mL) 30 minutes before exercise
Large eligible population: With millions of adults meeting the clinical criteria for obesity, insurers fear a financial tidal wave that threatens to overwhelm their budgets and destabilize premium costs